Business Description
Oculis Holding AG
ISIN : CH1242303498
Total Employee Number:
60Description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 89.77 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -30.9 | |||||
3-Year EPS without NRI Growth Rate | 45.8 | |||||
3-Year FCF Growth Rate | -20.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 67.01 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.93 | |||||
9-Day RSI | 68.52 | |||||
14-Day RSI | 54.41 | |||||
3-1 Month Momentum % | -55.18 | |||||
6-1 Month Momentum % | -52.24 | |||||
12-1 Month Momentum % | -24.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.35 | |||||
Quick Ratio | 8.35 | |||||
Cash Ratio | 8.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21 | |||||
Shareholder Yield % | -8.74 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -44.94 | |||||
ROA % | -36.87 | |||||
ROIC % | -248.59 | |||||
3-Year ROIIC % | -258.19 | |||||
ROC (Joel Greenblatt) % | -2881.39 | |||||
ROCE % | -43.84 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.88 | |||||
Price-to-Tangible-Book | 3.06 | |||||
EV-to-EBIT | -4.41 | |||||
EV-to-Forward-EBIT | -4.1 | |||||
EV-to-EBITDA | -4.45 | |||||
EV-to-Forward-EBITDA | -4.1 | |||||
EV-to-Forward-Revenue | 387.47 | |||||
EV-to-FCF | -5.28 | |||||
| Price-to-Net-Current-Asset-Value | 3.12 | |||||
| Price-to-Net-Cash | 3.2 | |||||
Earnings Yield (Greenblatt) % | -22.68 | |||||
FCF Yield % | -11.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OCS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oculis Holding AG Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.751 | ||
| Beta | 0.6121 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.21 | ||
| Volatility % | 68.59 | ||
| 14-Day RSI | 54.41 | ||
| 14-Day ATR ($) | 0.690337 | ||
| 20-Day SMA ($) | 11.86625 | ||
| 12-1 Month Momentum % | -24.78 | ||
| 52-Week Range ($) | 10.52 - 34.475 | ||
| Shares Outstanding (Mil) | 55.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oculis Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oculis Holding AG Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 12.07 (-0.25%) | ||
| Piper Sandler Virtual Ophthalmology Conference | 2026-07-10 09:30 | 13.70 (+0.15%) | ||
| 47th Annual Goldman Sachs Global Healthcare Conference | 2026-06-09 16:00 | 10.71 (-4.37%) | ||
| General meeting for 2026 | 2026-05-13 | 30.41 (-5.41%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 32.64 (+5.22%) | ||
| Needham Healthcare Conference | 2026-04-14 09:30 | 27.12 (-0.04%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 10:40 | 27.42 (+3.86%) | ||
| Annual report for 2025 | 2026-03-05 | 27.72 (+0.54%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 28.61 (-0.69%) |
Show
Entries
Oculis Holding AG Frequently Asked Questions
What is Oculis Holding AG(OCS)'s stock price today?
The current price of OCS is $12.88. The 52 week high of OCS is $34.48 and 52 week low is $10.52.
When is next earnings date of Oculis Holding AG(OCS)?
The next earnings date of Oculis Holding AG(OCS) is 2026-11-05.
Does Oculis Holding AG(OCS) pay dividends? If so, how much?
Oculis Holding AG(OCS) does not pay dividend.
Guru Commentaries on NAS:OCS
No articles.
Press Release
Articles on Oculis Holding AG
Headlines
See More- 1
Aug 10, 2026
Oculis to acquire worldwide rights to Privosegtor from Accure
Seeking Alpha • 2:56am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers